Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

BackgroundThe skeleton is a preferred site for prostate cancer metastasis, and once metastases occur, the disease becomes incurable. Increasing evidence indicates the prognostic value of skeletal-related parameters, but remains controversial.ObjectiveTo perform a systematic review of the existing li...

Full description

Bibliographic Details
Main Authors:	Tongyu Tong, Hanqi Lei, Yupeng Guan, Xiangwei Yang, Guolong Liao, Yamei Li, Donggen Jiang, Jun Pang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Oncology
Subjects:	metastatic castration-resistant prostate cancer skeletal-related parameters overall survival prognosis meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.586192/full

Similar Items

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
by: Lixin Mai, et al.
Published: (2020-12-01)

Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
by: Meagher MF, et al.
Published: (2023-11-01)

Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial
by: Byung Ha Chung, et al.
Published: (2023-01-01)

Current management of metastatic castration-sensitive prostate cancer
by: Adam Kessel, et al.
Published: (2021-01-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
by: DUAN Liqun, et al.
Published: (2019-09-01)

Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
by: Luc Cabel, et al.
Published: (2017-04-01)

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs
by: Turco F, et al.
Published: (2022-09-01)

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience
by: T. V. Ustinova, et al.
Published: (2021-12-01)

Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study
by: Jun Li, et al.
Published: (2021-01-01)

Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
by: Soraia Lobo-Martins, et al.
Published: (2020-07-01)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
by: Dhruv Bansal, et al.
Published: (2021-01-01)

Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study
by: Hao Xiang Chen, et al.
Published: (2023-07-01)

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
by: Yang Liu, et al.
Published: (2021-01-01)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
by: Sree M. Lanka, et al.
Published: (2023-04-01)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
by: Panagiotis J. Vlachostergios, et al.
Published: (2021-02-01)

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
by: Mike Wenzel, et al.
Published: (2021-04-01)

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer
by: Yozo Mitsui, et al.
Published: (2023-06-01)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: Luo J, et al.
Published: (2016-11-01)

Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer
by: Hui-Ming Lin, et al.
Published: (2021-10-01)

Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01)

Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Chun Wang, et al.
Published: (2021-01-01)

An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
by: Josephina P. M. Vrouwe, et al.
Published: (2021-10-01)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
by: Jian Pan, et al.
Published: (2022-12-01)

Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
by: Yuan-Chi Shen, et al.
Published: (2016-09-01)

Predictive factors for progression to metastatic castration-resistant prostate cancer
by: TAN Xintao, et al.
Published: (2021-03-01)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
by: Monica Vidal, et al.

A new method to quantify the effect of co-medication on the efficacy of abiraterone in metastatic castration-resistant prostate cancer patients
by: Bertalan Fekete, et al.
Published: (2023-09-01)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Albert Jang, et al.
Published: (2020-11-01)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
by: Edoardo Francini, et al.
Published: (2021-08-01)

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
by: Ali Alkan, et al.
Published: (2021-09-01)

Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients
by: Benedikt Hoeh, et al.
Published: (2021-11-01)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
by: Nicholas D. James, et al.
Published: (2022-11-01)

Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis
by: Omar Fahmy, et al.
Published: (2021-12-01)

A Rare Case of Castrate-Resistant Prostate Adenocarcinoma with a Unilateral Testicular Metastasis Mimicking a Primary Testicular Tumour
by: Jun Hee Hong, et al.
Published: (2022-11-01)

Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand
by: Bannakij Lojanapiwat, et al.
Published: (2017-03-01)

A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer
by: Diana V. Maslov, et al.
Published: (2023-03-01)

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
by: Neil M. Schultz, et al.
Published: (2018-09-01)

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
by: Pascoe Abigail C, et al.
Published: (2012-03-01)

Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
by: Tomas Pokrivcak, et al.
Published: (2024-04-01)